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Abstract
Purpose Breast cancer-related lymphedema (BCRL) is a de-
bilitating condition. The recommended treatment is based on
decongestive lymphedema therapy (DLT) with two separate
phases: a short-term intensive phase to reduce lymphedema
volume and a long-term maintenance phase to stabilize it.
Optimizing compression therapy and compliance during
maintenance phase are key factors for long-term control of
lymphedema. The primary objective of this pilot prospective
open-label randomized study was to assess the benefit of a
new auto-adjustable nighttime arm sleeve (MOBIDERM®
Autofit) on lymphedema volume during the maintenance
phase after the intensive phase.
Methods Forty women with BRCL were consecutively en-
rolled and randomized (D0) for 1 month in 1:1 ratio either in
night-use group: with MOBIDERM® Autofit (on top of a
daytime compression hosiery), or in no night-use group: with-
out MOBIDERM® Autofit (daytime hosiery alone). From
Day 31 to Day 90, al l pat ients were f i t ted with
MOBIDERM® Autofit. Primary endpoint was lymphedema
volume variation between Day 0 and Day 30. Secondary
endpoints were compliance, quality of life (LYMQOL arm
questionnaire), functional symptoms (heaviness, limb use lim-
itation, pain), sleep quality, and safety.
Results In ITT population, between Day 0 and Day 30, mean
lymphedema volume increase was higher in no night-use
group with 92.9 mL (i.e., 3.2%) than in night-use group with
46.7 mL (i.e., 1.80%), p = 0.757. Between Day 30 and Day
90, all patients fitted with MOBIDERM® Autofit, lymphede-
ma volume remained stable in both groups. The device im-
proved functional symptoms and function domain of the
LYMQOL arm questionnaire. MOBIDERM® Autofit was
worn overnight almost 85% of the nights. It was well accepted
by the patients and no adverse reaction leading to permanent
device discontinuation occurred.
Conclusions Our results suggest that MOBIDERM® Autofit
offers clinical benefits during maintenance phase of lymph-
edema treatment and enhances patient’s self-management.
Keywords Self-management .Lymphedema .Breast cancer .
Volume . Compression .Maintenance
Introduction
Breast cancer-related lymphedema (BCRL) is a common and
debilitating complication [1–3]. Despite modern treatment mo-
dalities, it remains a major health problem. As edema progress,
the disease can lead to pain, infection, decreased function, re-
duced quality of life, body image disturbance and anxiety [4, 5].
The recommended treatment of lymphedema is based
on a decongestive lymphedema therapy (DLT) which is
composed of 2 phases: an intensive phase which com-
bines manual lymphatic drainage (MLD), multilayer ban-
dages, skin cares, and physical exercises, to reduce as
much as possible lymphedema volume in a few days
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period of time and a maintenance phase which consists in
helping the patient to preserve lymphedema volume
achieved during intensive phase, as long as possible [6,
7]. In spite of self-care management, it is common to
observe an increase of lymphedema volume after inten-
sive phase also called Bmaintenance phase failure^. There
is no existing consensus on the definition of treatment
failure in lymphedema, but in the long-term trial of
Vignes et al. [8], the stringent definition of treatment fail-
ure, i.e., a lymphedema volume increase of ≥50% of the
total reduction obtained with the first intensive deconges-
tive physiotherapy, was selected to estimate a prolonged
benefit. With this end-point criterion, the risk of failure
was estimated to 38.1, 53.1, and 64.8% after 1, 2, and
4 years, respectively. In the POLIT study [9], the first
large observational study measuring the effects of DLT
in 12 French lymphology reference centers, Quéré et al.
[9] showed that even if intensive phase permitted to re-
duce lymphedema volume by 30%, the effect was partial-
ly reversed 6 months later. Therefore, optimizing mainte-
nance phase treatment seems to be crucial for long term
management of lymphedema.
Compression is largely described as the key compo-
nent in the treatment of lymphedema in the updated best
practice guidelines of International Lymphedema
Framework (ILF) [10]. In France, the Haute Autorité de
Santé (HAS) recommends to use high-pressure compres-
sion garments (up to 15 mmHg with the need to apply
the higher pressure tolerated by patient) during the day
and if needed, low stretched bandages during the night
without any pressure specifications [11]. More recently,
Damstra and Partsch [12] showed that applying too much
pressure under low-stretch bandages may be counterpro-
ductive and recommends levels of 20–30 mmHg for the
upper limb. Self-management and patient compliance to
treatment are crucial in the maintenance phase. Among
the 306 patients observed in POLIT study [8], mainte-
nance therapy was applied in most patients by means of
daytime hosiery (95.8%) and/or bandages (12.3%) mean-
ing some patients used both day devices. At night, 21.1%
of the patients did not use any night compression therapy.
Among the rest, 45.2% of the patients reported night
compression therapy using bandaging and 46% with
made to measure hosieries.
In practice, duringmaintenance phase, the bandages are not
easy to put on and require assistance and/or specific patient’s
education. Composed of several layers of inelastic and short-
stretch materials, these bulky bandages do not favor patient’s
compliance and quality of life. Custommade short-stretch arm
sleeve, designed to apply a low rest pressure, are easier to put
on but can be quickly unsuitable if patient’s measurements
vary over time. The challenge is to provide BCRL patients
with an easy to use, safe and effective low-stretch night device
as an add-on treatment to their daytime compression hosiery
in order to optimize their maintenance treatment and increase
their autonomy and compliance.
This study was conducted to assess the interest of nighttime
MOBIDERM® Autofit arm sleeve on lymphedema volume
during maintenance phase in patients with BCRL.
Patients and methods
Patient’s selection
This pilot prospective open-label randomized controlled trial
had been conducted between September 2014 and February
2015 in the vascular medicine ward of the Saint-Eloi Hospital,
Montpellier, France. Forty women were consecutively
screened and included. Eligible patients were women aged
≥18 years, with unilateral secondary upper limb lymphedema
of stage II or III according to the ISL classification, with ev-
ident pitting sign (assessed as ++ or +++). Patients had to have
undergone an intensive phase treatment with a decrease of
lymphedema volume at least of 10% prior to study entry.
Exclusion criteria were active cellulitis, lymphedema associ-
ated with active cancer requiring chemotherapy, motor and/or
sensitive neurological deficiency, postoperative edema (i.e.,
acute edema occurring in the days following breast cancer-
related surgery), active skin lesions on the arm, and pregnant
or breastfeeding female.
The studywas conducted in accordance with the Declaration
of Helsinki and the International Conference on Harmonization
Good Clinical Practice Guidelines (ICH-GCP). Prior to study
start, the protocol received approval from health authorities and
ethics committee. Written informed consent was obtained from
each patient prior to study enrolment.
Compression arm modalities
At the end of the intensive phase of the DLT (D0), pa-
tients fulfilling the study entry criteria were randomized in
a 1:1 ratio to:
& The night-use group (Group I), fitted during the first
30 days with MOBIDERM® Autofit device additionally
to their daytime elastic hosiery.
& The no night-use group (Group II), fitted only with the day
time elastic hosiery.
& The daytime elastic hosiery was standardized. It was a
circular made to measure knitted garment applying a level
of pressure of 15–20 mmHg (French class 2) or 20–
36 mmHg (French class 3) on investigator’s demand from
THUASNE company (THUASNE Lymphology®).
& Then, from Day 31 to Day 90, all patients in both groups
used both day and night time devices.
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Description of the medical device tested
The nighttime MOBIDERM® Autofit was a standard low-
stretch garment designed to apply a pressure of 15 mmHg. It
is an auto-adjustable semi-open sleeve (Thuasne, Saint-Etienne,
FRANCE) available in six sizes, two lengths, left/right arm
(Fig. 1) with several semi-rigid straps used to adjust the device
to each patient’s morphology or volumes changes. This gar-
ment uses the patented MOBIDERM® technology composed
of foam blocks in soft adherent webbing. It creates, on and
under the skin, zones of differentiated pressure between the
foam blocks and their perimeter allowing a local mobilization
to facilitate edema fluid evacuation.
Statistical analysis
The primary endpoint was the volume excess (also called
lymphedema volume) variation, defined as the volumetric dif-
ference of the affected limb compared to the contralateral up-
per limb, between Day 0 and Day 30. Volumes were calculat-
ed after taking patients measurements every 5 cm, above (4
measurements) and below (4 measurements) the fold of the
elbow (start point) and using the truncated cone formula: H ×
(C2 + C × c + c2)/12π, H = cone height, C = cone top circum-
ference, and c = cone base circumference. This method dem-
onstrated excellent inter- and intra-observer reproducibility in
comparison to water displacement, which is considered the
gold standard [13, 14].
The comparison of the volume excess variation (mL, %)
from Day 0 to Day 30 between the two randomization groups
was performed using a bilateral Wilcoxon-Mann-Whitney test
on the ITT population. All secondary endpoints and PP anal-
ysis were provided only descriptively: functional symptoms at
Day 30 and Day 90 vs. baseline, QOL based on LYMQOL
ARM questionnaire [15] at each study visits and patient’s
satisfaction with self-reported questionnaires, compliance of
the treatment evaluated by patient diary between Day 0 and
Day 30 and by questioning the patients at D90 regarding the
study period between Day 30 and Day 90.
Safety and tolerance data were assessed by numbers and
percentages of patients with at least one reported adverse event
(AE) tabulated by system organ class and preferred term.
As there is no previous specific published trial on night
garment in maintenance phase of lymphedema, sample size
calculation was not possible for this a proof of concept study.
Results
Patient disposition and baseline characteristics
Figure 2 displays patient’s disposal in the study. Forty
patients were randomized and included in the ITT and
safety populations. Five patients were excluded from the
per protocol (PP) population for major protocol violation;
3 patients in no night-use Group did not present any de-
crease of lymphedema volume after DLT, one patient in
night-use Group did not wear the daytime hosiery and the
nighttime hosiery for at least 75% of time and one patient
in no night-use Group applied a night or day different
compression device from the allocated one in the study.
Table 1 displays the baseline characteristics of the patients
and lymphedema. Overall, the mean age of the ITT population
was 67.0 years old [45.3; 89.9] and the mean body mass index
(BMI) was 28.5 kg/m2 [19.8; 44.0]. Disease characteristics
were well balanced between the two groups. Mean time from
diagnosis of lymphedema to inclusion was 8.3 years [0.5; 28.7].
The majority of the patients (92.2%) presented stage II
lymphedema with a pitting sign distributed between ++
(87.5%) and +++ (12.5%).
Efficacy results
Lymphedema volume variation for each time period analysis
(Day 0–Day 30–Day 90 and also according to the initiation of
intensive phase (DLT initiation)) is displayed in Fig. 3. At D0,
mean lymphedema volume variation was 436.9 mL ± 392.7
(range −0.5 to 1443.5) in the night-use group and
585.5 mL ± 397.7 (range −262.2 to 1493.1) in the no night-
use group. As shown in the figure, in the intent-to-treat (ITT)
population, the mean lymphedema volume variation at Day
30 (primary efficacy endpoint) was 46.7 mL ± 99.00 [0.41;
93.07] (i.e., median increase 1.8%) in the night-use group andFig. 1 Auto-adjustable MOBIDERM® Autofit
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was two times higher in the no night-use group,
92.9 mL ± 196.77 [0.77; 184.95] (i.e., median increase
3.2%), (p = 0.757). In the PP population (n = 35), the in-
between group difference was slightly more important with,
at Day 30, 51.36 mL ± 99.26 [3.72; 99.41] (i.e., median in-
crease 2.2%) in the night-use group vs. 108.27 mL ± 212.11
[−4.75; 221.30] (i.e., median increase 6.32%) in the no night-
use group.
From Day 30 to Day 90, when all patients were fitted with
MOBIDERM® Autofit, a stabilization of the lymphedema
volume was obtained in both groups (−1.2 mL in night-use
group vs. −0.3 mL in no night-use group).
During the intensive phase of DLT (before study period),
the mean lymphedema volume reduction was more important
in night-use group than in no night-use group (−236.2 mL
vs − 205.2 mL, respectively). From the initiation of the inten-
sive phase of the DLT to Day 30 of the maintenance phase,
mean lymphedema volume decreased by −189.5 mL in night-
use group and 112.3 mL in no night-use group and by
−190.7 mL in night-use group and −112.6 mL in no night-
use group at Day 90.
Functional symptoms at baseline were well balanced be-
tween groups (Fig. 4). At Day 30, a higher proportion of
patients in no night-use group complained with functional
symptoms (60 vs. 15% reported heaviness and/or pain, and
45% vs. 10% reported limb use limitation in no night-use
group vs. night-use group, respectively). The same trend
was observed until Day 90 with always 60% (n = 12/20) in
no night-use group having reported heaviness and /or pain
symptoms vs. 25% (n = 5/20) in night-use group. Limb use
Night-use group (Group I) 
Day-time THUASNE lymphology hosiery + night-
time MOBIDERM® Autofit device 
(N = 20) 
Intensive phase of Decongestive Lymphedema 
Therapy (DLT) 
N=40 
No night-usegroup (Group II) 
Day-time THUASNE lymphology hosiery only  
(N=20) 
Inclusion Visit (Day 0) 
Randomization 
N=40
Treated and completed study (Day 90 visit) 
(N = 20) 
Population of analysis 
ITT=20 
PP= 19 (95.0%) 
Treated and completed study (Day 90 visit)
(N = 20) 
Population of analysis 
ITT= 20 
PP= 16 (80.0%) 
Both night-use and no night-use groups (Day 30 visit) 
Day-time THUASNE lymphology hosiery + night-time MOBIDERM® Autofit device 
until Day 90









Fig. 2 Disposition of patients in the study
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limitation was reported in 20% (n = 4/20) of the patients in
night-use group vs. 40% (n = 8/20) in no night-use group at
the end of the study period.
Treatment exposure and compliance to the medical
devices
During the first month (Day 0–Day 30), the daytime hosiery
was worn all day long for a mean of 79 and 93% of the days by
night-use group and no night-use group patients, respectively.
The MOBIDERM® Autofit was worn all night long for a
mean of 84.5% of the nights.
Between Day 30 and D90, 94.7% (n = 18/19) wore the
daytime arm sleeve every day in night-use group and 90%
(18/20) in no night-use group. The MOBIDERM® Autofit
was worn every night by 79% (n = 15/19) and 95% (n = 19/
20) of the patients in night-use group and no night-use
group, respectively.
Table 1 Patient’s demographics and lymphedema characteristics
Group I




Total N = 40
Age at inclusion (years) N 20 20 40
Mean ± SD 65.11 ± 8.62 68.87 ± 11.79 66.99 ± 10.37
Median 64.47 72.01 66.31
Min; max 50.5; 84.5 45.3; 89.9 45.3; 89.9
Body mass index (kg m−2) at day 0[b] N 20 20 40
Mean ± SD 27.44 ± 4.54 29.63 ± 6.53 28.53 ± 5.66
Median 28.09 29.08 28.81
Min ; Max 20.4; 34.3 19.8; 44.0 19.8; 44.0
Time since diagnosis of breast cancer (years) N 20 20 40
Mean ± SD 12.72 ± 9.87 15.40 ± 11.21 14.06 ± 10.51
Prior therapies for breast cancer N 20 20 40
Surgery 20 (100.0%) 20 (100.0%) 40 (100.0%)
Time since latest surgery (years) Mean ± SD 10.78 ± 8.80 12.44 ± 9.39 11.61 ± 9.02
Type of surgery
Tumorectomy 5 (25.0%) 7 (35.0%) 12 (30.0%)
Tumorectomy + sentinel lymph node removal
and/or entire lymph node removal
5 (25.0%) 7 (35.0%) 12 (60%)
Mastectomy 3 (15.0%) 3 (15.0%) 6 (15.0%)
Mastectomy + entire lymph node removal
or entire lymph node removal
7 (35.0%) 3 (15.0%) 10 (50.0%)
Sentinel lymph node removal 0 (0.0%) 0 (0.0%) 0 (0.0%)
Radiotherapy 20 (100.0%) 20 (100.0%) 40 (100.0%)
Chemotherapy 12 (60.0%) 12 (60.0%) 24 (60.0%)
Hormone therapy N 7 (35.0%) 7 (35.0%) 14 (35.0%)
Time since lymphedema diagnosis (years) N 20 20 40
Mean ± SD 7.08 ± 5.52 9.62 ± 7.98 8.35 ± 6.90
Median 7.00 7.13 7.00
Min; Max 0.5; 20.5 0.5; 28.7 0.5; 28.7
Lymphedema stage N 20 20 40
Stage II 20 (100.0%) 17 (85.0%) 37 (92.5%)
Stage III 0 (0.0%) 3 (15.0%) 3 (7.5%)
Pitting signs N 20 20 40
Absent 0 (0.0%) 0 (0.0%) 0 (0.0%)
+ 0 (0.0%) 0 (0.0%) 0 (0.0%)
++ 18 (90.0%) 17 (85.0%) 35 (87.5%)
+++ 2 (10.0%) 3 (15.0%) 5 (12.5%)
++++ 0 (0.0%) 0 (0.0%) 0 (0.0%)
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Safety and local tolerability
Overall, a total of 31 patients (77.5%) experienced at least one
AE for a total of 64 events (36 in night-use group and 28 in no
night-use group), of which 11 events (n = 8 patients i.e., 40%
of night-use group patients) were considered as device-relat-
ed. Most frequently related AEs to MOBIDERM® Autofit
arm sleeve were erythema (n = 5) and pruritis (n = 4), but
none of them were severe. No discontinuation related to AE
was observed in the trial. Two serious adverse events (SAEs)
occurred during the study, none was related to the study
device.
Assessment of skin tolerability showed that the most fre-
quent cutaneous reactions were skin compression marks
(n = 15, 8 in night-use group and 7 in no night-use group),
related to day compression sleeve by clinicians and rapidly
decreasing redness (n = 5). No feeling of heat was reported.
No significant variation of the hand’s volume, assessed at Day
30 and Day 90 as compared to Day 0, was observed, suggest-
ing absence of the lymphedema migration to the hand.
Quality of life, sleep quality and patient satisfaction
Overall QoL and by specific domains (symptoms, appearance,
mood, and function) were assessed over the study period. In
line with symptoms, function domain was improved in night-
use group (−0.4 pts) vs. no night-use group (+0.1 pts). Others
domains remained quite stable in both groups over the study
period. Sleep-related issues showed no alteration of sleep
throughout the study with the same sleep quality score in both
groups.
A total of 82% patients were globally satisfied by the auto-
adjustable MOBIDERM® Autofit. For 70% of the patients,
the device was considered easy or very easy to wear. Almost
three quarters of the patients reported that they did not have
any trouble sleeping with. The arm sleeve was assessed as
comfortable or very comfortable by more than 90% of the
patients. The pressure on the arm during the night was bear-
able for 87.2% of the patients.
Discussion
This is the first study evaluating the effects of the nighttime
auto-adjustable MOBIDERM® Autofit arm sleeve in women
with BCRL who had just completed intensive phase of DLT.
We observed a different variation of lymphedema volume
between the two groups in favor of the night-use group. In
the ITT population, the lymphedema volume variation from
Day 0 to Day 30 (relative median, primary efficacy endpoint)
was lower in patients fitted with MOBIDERM® Autofit
(night use group) vs. the no night-use group (1.8 vs. 3.2%,
respectively). The introduction during the first 30 nights of
Autofit in night-use group patients, a critical period following
intensive phase of DLT associated with high risk of
Fig. 4 Functional symptoms
evolution legend: the figure
shows the evolution of functional
symptoms (namely, heaviness
and/or pain, and limb use limita-
tion) at each study time points
(Day 0, Day 30 and Day 90) in
both treatment groups
Fig. 3 Volume excess variation–ITT set. The figure displays the mean
volume excess variations (mL) calculated using with circumferential
method in the two treatment groups at each time point (Day 30 and
Day 90) compared to Day 0 (baseline) and to the initiation of intensive
phase (DLT initiation)
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lymphedema volume increase, should have limited mainte-
nance phase failure, as compared to no night-use group pa-
tients treated without night device.
From Day 30 to Day 90, when all patients were fitted with
the auto-adjustable MOBIDERM®Autofit arm sleeve during
the night, the lymphedema volume remained stable in both
groups, suggesting that the device allowed stabilization of
the lymphedema volume as soon as it is putted on.
Interestingly, this stabilization observed in night-use group is
associated with improvement of the functional symptoms as
well as the function as assessed by the patients.
High quality compressive garments are important to main-
tain and optimize the volume reduction achieved during the
intensive phase of DLT. Long term and consistent use of gar-
ments or bandages during the night are encouraged by ILF
[10]. Vignes et al. [8] showed that womenwhowore a daytime
compression sleeve associated with nighttime low-stretch
compression bandages had a significantly reduced risk of re-
lapse in arm lymphedema volume. However, self-bandaging
remain a difficult process for patients, especially for arm. In
addition, multilayers bandages composition varies widely
(number of layers, type of material, number of overlaps) and
the final quality is operator-dependent. Our results showed
that MOBIDERM® Autofit night sleeve can stabilize lymph-
edema volume during the first 3 months of the maintenance
phase and improve some domains of quality of life and func-
tional symptoms as an add-on treatment.
Patient’s adherence to the therapy is an important fac-
tor in the long-term management of lymphedema. It has
been shown that the persistence of reduced lymphedema
volume is associated with good patient’s compliance [16].
In our study, during the first month, MOBIDERM®
Autofit was worn all night long for a mean of 84.5% of
the nights. The same levels of compliance are observed
from D30 to D90 in both groups, confirming the high
acceptability of the device by patients. This result is in
accordance to the great satisfaction reported by patients
who especially liked the speed to put it on and the auto-
adjustable nature of the product giving patients autonomy
and opportunity to take part of their own treatment. Our
data also proved that this device has a good safety profile,
which could be a contributing factor to the observed good
compliance.
This original proof of concept study shows that night arm-
sleeve MOBIDERM® Autofit can be a useful device to sta-
bilize lymphedema volume during maintenance phase treat-
ment. The benefit seems to be greater in case of early treat-
ment initiation after DLT intensive phase. Moreover, the study
shows that it is a well-accepted device that enhances patient’s
autonomy. Consecutive inclusion over a short period in a sin-
gle site limited the selection bias; also it is worth noting that,
the study population and lymphedema characteristics is repre-
sentative of the population of patients with BCRL.
The limit of the study is the small sample size to show
the statistical significance. As there are very few articles
dealing precisely on the maintenance phase of lymphede-
ma therapy and specifically on night garment effect, it
was difficult to initially hypothesis the treatment effects.
The results need to be confirmed in an appropriately
powered study.
Conclusion
The results of this study suggest that auto-adjustable
MOBIDERM®Autofit night sleeve, on top of daily compres-
sion, offer benefit to patients during maintenance phase of
lymphedema treatment and enhances patient’s autonomy.
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